Speaker(s): 

Simran Kaur, PharmD, Resident I, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Sarah F. Hale, PharmD, BCPPS, Director of Pharmacy, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• List appropriate oral anticoagulation and oral antiplatelet agents for patients with Atrial Fibrillation (Afib) and post-Percutaneous Coronary Intervention (PCI).
• Identify appropriate candidates for transitioning from combination therapy to monotherapy and the timing of this in clinical practice.
• Compare the efficacy and safety of monotherapy versus combination therapy in patients with AFib after PCI with drug-eluting stent(s). 

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brian Simpkins, PharmD, Jessica Milheim, CPhT, Clara Bishay, PharmD, and Simran Kaur, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.